GLPwatch
Papers (9189)
Page 97 of 154, ranked by citation count.
- When should fixed ratio basal insulin/glucagon-like peptide-1 receptor agonists combination products be considered?
- Biased agonists with less glucagon-like peptide-1 receptor-mediated endocytosis prolong hypoglycaemic effects.
- Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence.
- The Differential and Combined Action of Insulin Glargine and Lixisenatide on the Fasting and Postprandial Components of Glucose Control.
- Inhibitory effects of peripheral administration of exendin-4 on food intake are attenuated by lesions of the central nucleus of amygdala.
- A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
- Incretin attenuates diabetes-induced damage in rat cardiac tissue.
- Glucose-Responsive Nanochaperones Mediate Exendin-4 Delivery for Enhancing Therapeutic Effects.
- Control of liver glucokinase activity: A potential new target for incretin hormones?
- A Retrospective Comparative Analysis of Cutaneous Adverse Reactions in GLP-1 Agonist Therapies.
- Dietary salt promotes cognition impairment through GLP-1R/mTOR/p70S6K signaling pathway.
- Network meta-analysis of liraglutide versus dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes in Japanese patients.
- Semaglutide and GLP-1 analogues as weight-loss agents.
- Early clinical studies with liraglutide.
- Liraglutide, a GLP-1 agonist, as a new adjunct treatment in Hailey-Hailey disease: a case report.
- Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.
- Expectations and Outcomes From Glucagon-Like Peptide-1 Receptor Agonists As Adjunct Treatment for Type 1 Diabetes - Case Presentations.
- Simultaneous analysis of antihyperglycemic small molecule drugs and peptide drugs by means of dual liquid chromatography high-resolution mass spectrometry.
- Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women.
- Development and validation of a rapid high-performance liquid chromatography method for the quantification of exenatide.
- Pharmaceutical Therapies for the Treatment of Obesity: A Network Meta-analysis.
- Comparison of efficacy and safety of insulin degludec/liraglutide and insulin glargine U-100/lixisenatide in individuals with type 2 diabetes mellitus using professional continuous glucose monitoring.
- The GLP-1 agonist, exendin-4, stimulates LH secretion in female sheep.
- Should tirzepatide be considered for early management in type 2 diabetes? Pros and cons.
- Anti-obesity drug also protects against heart disease - what happens next?
- Efficacy and safety of lixisenatide as add-on therapy to basal insulin in older adults with type 2 diabetes in the GetGoal-O Study.
- Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence.
- Antinociceptive Behavior, Glutamine/Glutamate, and Neopterin in Early-Stage Streptozotocin-Induced Diabetic Neuropathy in Liraglutide-Treated Mice under a Standard or Enriched Environment.
- Short-Term Effectiveness and Reduction in Insulin Requirements in Patients With Type 2 Diabetes Treated With IdegLira in a Real-World Setting.
- Hypoglycemia in patients with type 2 diabetes using concomitant exenatide BID and long-acting insulin therapy.
- Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes.
- Tirzepatide to treat obesity: phase III results.
- Semaglutide, Obesity-Related Heart Failure, and Type 2 Diabetes. Reply.
- The role of glucagon in the possible mechanism of cardiovascular mortality reduction in type 2 diabetes patients.
- A mouse model of weight gain after nicotine withdrawal.
- Four weeks treatment with the GLP-1 receptor analogue liraglutide lowers liver fat and concomitantly circulating glucagon in individuals with overweight.
- Semaglutide, a newly available glucagon-like peptide receptor agonist, shows remarkable favorable effects in hemodialysis patients with obesity and Type 2 diabetes.
- Incretin effect of glucagon-like peptide 1 receptor agonist is preserved in presence of ABCC8/SUR1 mutation in β-cell.
- Linearity of β-cell response across the metabolic spectrum and to pharmacology: insights from a graded glucose infusion-based investigation series.
- The Potential Role of GLP1-RAs Against Anticancer-Drug Cardiotoxicity: A Scoping Review.
- South Asian consensus guideline: Use of GLP-1 receptor agonists during Ramadan: Update 2016 Revised Guidelines on the use of GLP-1A in Ramadan.
- Liraglutide chronic treatment prevents development of tolerance to antiseizure effects of diazepam in genetically epilepsy prone rats.
- Severe, prolonged thrombocytopenia in a patient sensitive to exenatide.
- Continuous Glucose Monitoring and the Effect of Liraglutide in Cardiac Surgery Patients: A Substudy of the Randomized Controlled GLOBE Trial.
- Impact of short and long exposure to cafeteria diet on food intake and white adipose tissue lipolysis mediated by glucagon-like peptide 1 receptor.
- Glucagon-like peptide-1 analog therapy in rare genetic diseases: monogenic obesity, monogenic diabetes, and spinal muscular atrophy.
- MR Assessed Changes of Renal Sinus Fat in Response to Glucose Regulation in West European and South Asian Patients With Type 2 Diabetes.
- Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis.
- Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study).
- Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?
- Liraglutide toxicity presenting to the emergency department: A case report and literature review.
- Weight Loss Induces Changes in Vitamin D Status in Women With Obesity But Not in Men: A Randomized Clinical Trial.
- Rational combination therapy for type 2 diabetes.
- Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer's disease.
- Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits Aβ25-35-induced apoptosis in PC12 cells by suppressing the expression of endoplasmic reticulum stress-related proteins.
- Association between GLP-1 RAs and DPP-4 inhibitors with biliary disorders: pharmacovigilance analysis.
- Application of novel peptide (Pp1) improving the half-life of exendin-4 in vivo.
- Tirzepatide decreases systolic and diastolic blood pressure.
- Euglycemic Ketoacidosis Caused by Sodium-Glucose Cotransporter 2 Inhibitors: A Case Report.
- Cross-Sectional Analysis of Adverse Dermatologic Events Reported to the FDA After Use of GLP-1 Agonists.